Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Lipocine Price Performance

NASDAQ:LPCN opened at $4.90 on Tuesday. The stock’s 50-day moving average is $5.14 and its two-hundred day moving average is $5.43. Lipocine has a fifty-two week low of $2.44 and a fifty-two week high of $11.79. The stock has a market cap of $26.22 million, a PE ratio of -6.45 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. On average, equities research analysts anticipate that Lipocine will post -0.78 earnings per share for the current year.

Institutional Trading of Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC raised its position in Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the period. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.